Make better decisions with better MRD testing
Unmatched sensitivity and specificity for confident MRD detection. Interested in learning more about using Haystack MRD™?
MRD testing
See what other tests can't
Haystack Oncology uses the next generation of circulating tumor DNA (ctDNA) detection technology to see through the noise and uncover residual, recurrent, and resistant disease earlier than any other minimal residual disease (MRD) test.
Haystack MRD
Haystack MRD
MRD testing demands the most sensitive ctDNA detection. The Haystack MRD Test is a tumor-informed ctDNA test that is specifically designed for post-surgical MRD applications.
Residual disease detection
Go beyond standard risk assessment for adjuvant chemotherapy guidance to ensure that the right person gets the right treatment.
Treatment response monitoring
Disease recurrence surveillance
Detect molecular recurrence with greater lead time before clinical relapse.


Haystack MRD
Dive Deeper
Haystack Oncology was founded to dramatically improve patient outcomes by optimizing treatment strategies using transformative precision oncology. Learn how we support clinicians and biopharma in our mission by providing better MRD testing for better clinical management and therapeutic development.



The Difference
Why choose Haystack MRD?
Analytical superiority
Transformative technology
Built by giants
Haystack Oncology was founded by pioneers in blood-based diagnostics who were the first to envision a revolution in patient care made possible by groundbreaking molecular methods.
News & Events
The Latest
Find out what's happening at Haystack Oncology and stay up-to-date with industry news.
Quest Diagnostics Completes Acquisition of Haystack Oncology, Adding Sensitive MRD Liquid Biopsy Technology to Cancer Diagnostics Portfolio
SECAUCUS, N.J., June 21, 2023 /PRNewswire/ -- Quest Diagnostics (NYSE:DGX), the nation's leading provider of diagnostic information services, to ...
2023 ASCO Annual Meeting
We are excited to announce that Haystack Oncology will be participating in the American Society for Clinical Oncology (ASCO) annual meeting in Chicago, Il ...